Pharsight Establishes Phoenix® Center of Excellence Program, Names Five Leading Pharmacometrics Programs as Charter Members
Collaboration Strengthens Relationships Between Pharsight and Leading Universities Training the Next Generation of Drug-Disease Modelers
ST. LOUIS–(BUSINESS WIRE)–Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, announced today that it has named five leading universities as Phoenix Centers of Excellence as part of its continuing collaboration with academic departments and research organizations worldwide.
The Phoenix Centers of Excellence Program is a collaboration with Pharsight to enhance research and training in pharmacometrics at several elite academic centers. More than 350 pharmacy and medical schools worldwide currently use Pharsight software for teaching and research purposes.
The five Pharsight Phoenix Centers of Excellence are:
- The University of Auckland School of Medicine, Department of Pharmacology and Clinical Pharmacology
- The State University of New York (SUNY) at Buffalo School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences
- The University of Minnesota School of Pharmacy, Department of Experimental and Clinical Pharmacology
- Uppsala University Faculty of Pharmacy, Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy
- The University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics.
The Centers of Excellence will collaborate with Pharsight to promote excellence in pharmacometrics through topical lectures and webinars on the application of model-based approaches to improve drug development knowledge and decision-making. The Centers of Excellence will also participate in other activities designed to recognize important contributions to the field of pharmacometrics through expanded access to Pharsight software, including Phoenix®, Pharsight’s desktop software platform for pharmacokinetic and pharmacodynamic (PKPD) data analysis and modeling.
“Since its inception, Pharsight has been fortunate to have the support of outstanding teachers in the field of pharmacometrics,” said Daniel Weiner, Ph.D., Senior Vice President and Chief Technology Officer of Pharsight. “Our deeper collaboration with these top academic centers will support their pivotal role in the training of tomorrow’s pharmacometrics practitioners, of which there is a widely recognized global shortage. We are pleased to share Pharsight’s tools with these leading institutions and look forward to further collaborations to strengthen the interdisciplinary field of model-based drug development.”
About Phoenix
Phoenix is Pharsight’s new desktop software platform that supports model-based drug development and its utility in translational science. Phoenix® WinNonlin® is the next generation of Pharsight’s industry standard software for PKPD modelin and noncompartmental analysis. Phoenix® NLME™ provides powerful new data processing and modeling tools for population PKPD analysis. Phoenix® Connect™ integrates applications built on the Phoenix platform with commonly used third-party analysis and modeling tools such as NONMEM®, R®, SAS® and S-PLUS®.
About Pharsight
Pharsight, a Certara™ company, is a market-leading provider of software products and scientific consulting services to help pharmaceutical and biotechnology companies improve their drug development process, regulatory compliance and strategic decision-making. Established in 1995, the company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight leverages expertise in its software tools and in the disciplines of pharmacology, drug and disease modeling, human genetics, biostatistics, strategic decision-making and regulatory strategy. Headquartered in St. Louis, Missouri, with more than 1200 customers worldwide, Pharsight products and services are used by all of the world’s top 50 pharmaceutical firms. More information about Pharsight is available at www.pharsight.com.
About Certara
Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos and Pharsight Corporation. More information about Certara is available at www.certara.com.
Registered Trademarks and Trademarks
Pharsight, Phoenix, Phoenix WinNonlin, Phoenix NLME, Phoenix Connect and Certara are trademarks or registered trademarks of Tripos, L.P. All other brands and product names are trademarks or registered trademarks of their respective holders.
